General pharmacology, toxicology and future clinical development of HOE 077.
The prolylhydroxylase inhibitor HOE 077 which has proven to be liver-selective in animals was tested in general pharmacological and toxicological studies for unwanted effects and safety. The results of these studies permit clinical development. A single-dose study in healthy volunteers was performed which showed that kinetics and main metabolites in man were similar to those found in animals. Aspects of the future clinical development of HOE 077 are discussed.[1]References
- General pharmacology, toxicology and future clinical development of HOE 077. Horn, W. J. Hepatol. (1991) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg